Europe In-Vitro Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Europe In-Vitro Diagnostics Market is Segmented by Technology, Product (Instruments, Reagents, and Other Product), Usability, Application, End User, and Geography.

Market Snapshot

Study Period: 2018 - 2026
Base Year: 2020
CAGR: 5.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The European in-vitro diagnostics market is expected to register a CAGR of 5.5%, over the forecast period. Major factors that are fueling the market include a rapid increase in chronic diseases, increasing demand for point-of-care testing and personalized medicine, and technological advances, along with the rising geriatric population in the country. In addition, patients can deal with their conditions better with the help of IVDs (diabetic patients can use portable blood glucose monitors on a regular basis, to determine their blood glucose level). Therefore, the demand for IVD products is influenced by an increase in the incidences of chronic diseases. As the demand for IVD is increasing, the market in Europe is expected to healthy growth with the presence of many manufacturers and research activities going across many countries.

Scope of the Report

IVDs are tests performed in laboratories or by consumers at homes, to diagnose, monitor, screen, and assess various diseases, conditions, or infections. IVD products are reagents, instruments, and systems that are intended for use in the diagnosis of diseases or other conditions. IVDs form an essential part of the current healthcare system. They reduce hospital stays and the need to recuperate.

By Test Type
Clinical Chemistry
Molecular Diagnostics
Immuno Diagnostics
Other Test Types
By Product
Other Products
By Usability
Disposable IVD Devices
Reusable IVD Devices
By Application
Infectious Disease
Autoimmune Disease
Other Applications
By End User
Diagnostic Laboratories
Hospitals and Clinics
Other End Users
United Kingdom
Rest of Europe

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Instrument Segment is Expected to Experience Good CAGR over the Forecast Period

The instrument segment encompasses the apparatus or devices, which are used alone or in combination, and are intended by the manufacturer for the in-vivo examination of specimens derived from the human body, solely to provide information for diagnostics, monitoring, or compatibility purposes. Examples of IVD instruments include coagulation test systems, urine test strips, pregnancy tests, blood sugar monitoring systems, slide processing systems, cell imaging and analysis systems, and IVD assay and PCR testing platforms, like Abbott’s Abbott m2000 RealTime System. One of the primary growth drivers of IVD instruments is the increasing adoption of multi-test platforms. In-vitro diagnostic testing through the use of multi-test platforms has the added advantage of allowing multiple different markers to be detected at once. This is particularly advantageous when screening for the presence of drugs in a patient. Rising acceptance of routine diagnostic and the advent of precision and personalized medicine are likely to drive the growth of the instrument segment of the market in Europe, over the forecast period.


Competitive Landscape

The European in-vitro diagnostics market is consolidated in nature, due to the presence of many market players. The major market players in Europe are focusing on partnerships and agreements to enhance their market presence. For instance, in April 2019, QIAGEN and NeuMoDx expanded the assay menu for their next generation of fully integrated PCR systems for clinical laboratories in Europe. They also announced the availability of NeuMoDx 96 version. The major players include Roche Diagnostics, Abbott Laboratories, Bio-Rad Laboratories Inc., Danaher Corporation, and Thermo Fisher Scientific Inc., who hold large shares in this market. However, with the help of product innovation and technological advancements, there is a possibility of new players entering the market in the future.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rapid Increase in Chronic Diseases

      2. 4.2.2 Increasing Number of Private Hospitals and Independent Testing Laboratories

      3. 4.2.3 Increasing Demand for Point-of-care Testing and Personalized Medicine

      4. 4.2.4 Technological Advancements by Medical Devices Companies

    3. 4.3 Market Restraints

      1. 4.3.1 Stringent Regulations

      2. 4.3.2 Cumbersome Reimbursement Procedures

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Test Type

      1. 5.1.1 Clinical Chemistry

      2. 5.1.2 Molecular Diagnostics

      3. 5.1.3 Hematology

      4. 5.1.4 Immuno Diagnostics

      5. 5.1.5 Other Test Types

    2. 5.2 By Product

      1. 5.2.1 Instrument

      2. 5.2.2 Reagents

      3. 5.2.3 Other Products

    3. 5.3 By Usability

      1. 5.3.1 Disposable IVD Devices

      2. 5.3.2 Reusable IVD Devices

    4. 5.4 By Application

      1. 5.4.1 Infectious Disease

      2. 5.4.2 Diabetes

      3. 5.4.3 Cancer/Oncology

      4. 5.4.4 Cardiology

      5. 5.4.5 Autoimmune Disease

      6. 5.4.6 Nephrology

      7. 5.4.7 Other Applications

    5. 5.5 By End User

      1. 5.5.1 Diagnostic Laboratories

      2. 5.5.2 Hospitals and Clinics

      3. 5.5.3 Other End Users

    6. 5.6 Geography

      1. 5.6.1 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe


    1. 6.1 Company Profiles

      1. 6.1.1 Abbott Laboratories

      2. 6.1.2 Becton, Dickinson and Company

      3. 6.1.3 Bio-Rad Laboratories Inc.

      4. 6.1.4 Danaher Corporation (Beckman Coulter, Inc)

      5. 6.1.5 Johnson & Johnson

      6. 6.1.6 Roche Diagnostics

      7. 6.1.7 Siemens Healthcare

      8. 6.1.8 Thermo Fisher Scientific Inc.

      9. 6.1.9 Sysmex Corporation

      10. 6.1.10 QIAGEN

      11. 6.1.11 BioMerieux SA

      12. 6.1.12 Tesa SE

    2. *List Not Exhaustive

**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Europe In-Vitro Diagnostics Market market is studied from 2018 - 2026.

The Europe In-Vitro Diagnostics Market is growing at a CAGR of 5.5% over the next 5 years.

Sysmex Corporation, QIAGEN, Tesa SE, BioMérieux SA, F. Hoffmann-La Roche Ltd are the major companies operating in Europe In-Vitro Diagnostics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!